Investigational Myeloma Treatment KP1237 Wins FDA Orphan Drug Status
The U.S. Food and Drug Administration (FDA) has…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
FDA Puts on Hold Phase 1 Cellectis Trial Testing CAR T-cell Therapy UCARTCS1A
A Phase 1 trial assessing Cellectis’ investigational…
LLS Highlights Its Support Programs During Blood Cancer Awareness Month
Throughout September for Blood Cancer Awareness Month, the…
Melflufen Combo Earns FDA Priority Review for Triple-refractory Myeloma
The U.S. Food and Drug Administration (FDA) has…
Trial Begins Dosing of ‘Off-the-shelf’ CAR T-cell Therapy for Multiple Myeloma
The first patient has been dosed in a Phase…
Cilta-cel, CAR T-cell Treatment, Named Breakthrough Therapy in China
Legend Biotech and Janssen’s investigational CAR…
